World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
UK
2026

D-Index & Metrics

Best Scientists

D-Index
169
Citations
142184
World Ranking
894
National Ranking
93

Medicine

D-Index
172
Citations
151257
World Ranking
484
National Ranking
58

David Cunningham publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David Cunningham sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,639 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David Cunningham D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David Cunningham sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 172 D-Index — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

David Cunningham is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research primarily focuses on the field of Medicine, with a significant concentration on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery, and Cancer Research.

The main topics of David Cunningham's work include:

  • Lymphoma Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Esophageal Cancer Research and Treatment
  • CAR-T cell therapy research
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics

Recent notable papers authored or co-authored by Cunningham include:

  • "Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial" (2022, Journal of Clinical Oncology)
  • "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" (2020, Blood)
  • "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study" (2021, The Lancet)
  • "Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial" (2022, The Lancet. Gastroenterology & Hepatology)
  • "Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C" (2023, New England Journal of Medicine)

Frequent co-authors collaborating with Cunningham include:

  • Ian Chau (72 co-authorships)
  • Naureen Starling (59 co-authorships)
  • Ruwaida Begum (32 co-authorships)
  • Sheela Rao (27 co-authorships)
  • Bhupinder Sharma (27 co-authorships)

Cunningham has published extensively in various scientific journals. Venues with significant numbers of publications include:

  • Journal of Clinical Oncology (30 publications)
  • Annals of Oncology (19 publications)
  • Blood (14 publications)
  • British Journal of Haematology (11 publications)
  • European Journal of Cancer (7 publications)

In addition to journal articles, Cunningham has contributed to book publications, including one titled Ruling by Other Means released in 2020 by Cambridge University Press, which has been cited in subsequent research.

Best Publications

  • Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

    David Cunningham;William H. Allum;Sally P. Stenning;Jeremy N. Thompson

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

    Juan Ignacio Valle;Harpreet Singh Wasan;Daniel H Palmer;David Cunningham

  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    J Y Douillard;D Cunningham;Arnaud Roth;M Navarro

  • Capecitabine and oxaliplatin for advanced esophagogastric cancer.

    David Cunningham;Alicia F C Okines;Sue Ashley

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli

  • The role of probiotics in aquaculture

    José Luis Balcázar;Ignacio de Blas;Imanol Ruiz-Zarzuela;David Cunningham

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

    David Cunningham;Seppo Pyrhönen;Roger D James;Cornelis J A Punt

  • Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

    John P. Neoptolemos;Deborah D. Stocken;Claudio Bassi;Paula Ghaneh

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    A. Okines;M. Verheij;W. Allum;D. Cunningham

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

    Robert Marcus;Kevin Imrie;Andrew Belch;David Cunningham

  • Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin

    S J Arnott;D Cunningham;J Gallagher;R Gray

  • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

    A Webb;D Cunningham;J H Scarffe;P Harper

  • European evidence-based guidelines on pancreatic cystic neoplasms

    Marco Del Chiaro;Marc G. Besselink;Lianne Scholten;Marco J. Bruno

Frequent Co-Authors

Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust
A. R. Norman
A. R. Norman Royal Marsden NHS Foundation Trust
Andrew Wotherspoon
Andrew Wotherspoon Royal Marsden NHS Foundation Trust
Gina Brown
Gina Brown Imperial College London
Juan W. Valle
Juan W. Valle University of Manchester
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Bengt Glimelius
Bengt Glimelius Uppsala University
John Radford
John Radford University of Manchester
David C. Linch
David C. Linch University College London
John P. Neoptolemos
John P. Neoptolemos Heidelberg University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a medical career in the USA is diverse, with multiple educational avenues available online. If you are looking for a patient-facing career without a long admissions process, consider exploring the easiest nursing schools to get into. These programs often offer flexible admissions and support for aspiring nurses at all stages.

Some online ABSN programs let you skip common standardized tests, such as the TEAS or HESI. If you’re seeking an alternative pathway, browse absn programs that don't require teas to find accessible options.

Beyond clinical roles, administrative and support positions are also in demand. Those interested in healthcare administration may benefit from pursuing the best online healthcare administration degree for leadership and management roles. Alternatively, if you prefer office-based work, you can explore reputable medical billing and coding online schools that accept financial aid.

Whether you’re aiming for direct patient care or a specialized administrative path, these educational options make it easier to pursue a healthcare career that fits your goals.

Best Scientists Citing David Cunningham

Trending Scientists

Recently Published Articles